SINGAPORE —Clinical research organization Novotech has signed a definitive agreement to purchase Australian bioanalytical testing firm Agilex Biolabs from a subsidiary of healthcare provider Healius Limited. The acquisition remains subject to customary closing conditions and regulatory approvals before final execution.
Integrating Agilex Biolabs into Novotech’s network expands the buyer’s laboratory capabilities in Australia, reinforcing its position in early-stage clinical trial execution across the Asia-Pacific territory. Agilex Biolabs operates specialized bioanalytical facilities in Adelaide, offering contract research support to international pharmaceutical and biotechnology sponsors.
Novotech is a full-service global clinical research organization providing scientific advisory and trial management services across Asia-Pacific, North America, and Europe. Backed by private equity investors including TPG, Temasek, and GIC, the company maintains partnerships with over 5,000 trial sites worldwide. Healius Limited is an Australian healthcare enterprise specializing in pathology services and diagnostic network operations across Australia.
This transaction highlights growing demand for integrated contract research and specialist laboratory services in primary early-phase clinical destinations. Australia continues to attract international drug developers due to favorable regulatory frameworks and efficient research infrastructure, driving consolidation among specialized service providers to deliver end-to-end development capabilities.
